Phase I/II Trial Evaluation of Radiol... - Advanced Prostate...

Advanced Prostate Cancer

22,350 members28,110 posts

Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant PCa with [161Tb]Tb-PSMA-I&T

Maxone73 profile image
8 Replies

and it's supposed to do a better job than Lutetium (Pluvicto)

But keep an eye also on 64 Cu SAR Bispsma, which had some incredible results, and of course Actinium....honestly on paper they all seem to be better than Lutetium, well, after all we are evolving...

urotoday.com/recent-abstrac...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
8 Replies
Cenerus profile image
Cenerus

TB-161 does look really interesting. Unlike Lutetium-177 it gives off high LET auger electrons that can act over short distances that should kill micromets which is the main reason lutetium isn't durable and is just a palliative. It's also much easier to produce than lutetium, so should be cheaper and more plentiful. I'm kind of surprised that it didn't get looked at before lutetium-177 given its better overall performance. If this or Actinium or Astatine finally reach the market, they'll make lutetium obsolete.

Maxone73 profile image
Maxone73 in reply toCenerus

I know that there are always exceptiona responders...but here is a gift for you (in case you haven't read about this before): guoncologynow.com/post/comp... 😀

Cenerus profile image
Cenerus in reply toMaxone73

I saw that about CU-67. And when you look at CU-67 next to TB-161, the numbers for TB-161 look much more impressive at the level of small volumes down around 5-10 microns where single cells in micrometastasis live.

Maxone73 profile image
Maxone73 in reply toCenerus

Even better then!

rfgaus profile image
rfgaus

With low SE's and high efficacy to destroy cancer at the cellular level, it would be nice to see these novel Radiogland treatments approved for earlier use in Standard of Care Protocols. Having to go through and fail palliative ADT and Chemo treatments with all their physically destructive SE's to get to something effective is frustrating.

V10fanatic profile image
V10fanatic

"positive disease on [68Ga]Ga-PSMA-11 or [18F]DCFPyL PET/CT (SUVmax ≥ 20); no sites of discordance on [18F]FDG PET/CT"

Yet another new treatment path that won't work for me :-(

Maxone73 profile image
Maxone73 in reply toV10fanatic

Why???

V10fanatic profile image
V10fanatic in reply toMaxone73

My last round of PSMA-PETs came back clear, yet an FDG-PET showed 4 mets.

Not what you're looking for?

You may also like...

CAR T-Cell Use Possible in Metastatic Castration-Resistant Prostate Cancer

A few years off but one to keep an eye on. CAR T-Cell Use Possible in Metastatic...

Overall Survival With [177]Lu-PSMA-617 vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

The Lancet Oncology TAKE-HOME MESSAGE TheraP was a phase II trial that compared the efficacy of...
Magnus1964 profile image

Patterns of Cancer Progression of Metastatic Hormone-sensitive PCa in the ECOG3805 CHAARTED Trial

New CHAARTED paper below [1]. "Reliance on prostate-specific antigen (PSA) alone is an inadequate...
pjoshea13 profile image

Pembrolizumab in Patients With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

TAKE-HOME MESSAGE •Pembrolizumab is currently only FDA-approved for men with microsatellite...
Balsam01 profile image